AMD and DME: Addressing the Disease Burden, Treatment Challenges, and Opportunities for Improved Management

This activity is part 1 in a 3-part webinar curriculum.

Program Description

Patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) experience significant disease- and treatment-related burdens, such as a higher risk of mortality and frequency of injections, that negatively impact their quality of life and contribute to adherence issues. Specialty pharmacists can assist patients in addressing these burdens through identification of appropriate management strategies and treatment advances for AMD and DME to ensure improved adherence. Pharmacists should be also aware of the differentiating factors that influence treatment decisions for a patient. This first webinar of the curriculum will highlight challenges patients with AMD and DME experience, as well as opportunities to improve the quality of patient care with new and emerging therapies.

Target audience: Specialty pharmacists

Type of activity: Application
Release date: August 10, 2023
Expiration date: August 10, 2024

Time to complete activity: 1.0 hour

Learner level: Foundational, intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the pathophysiology and risk factors of age-related macular degeneration (AMD) and diabetic macular edema (DME)
• Determine the disease burden, including the challenges with AME and DME traditional treatment therapies and the opportunities for improvement in quality of patient care
• Identify new and emerging therapies that address the treatment challenges and gaps associated with AMD and DME

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-325-H01-P. The activity is available for CE credit through August 10, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Joshua Mali, MD, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Samsara Vision

Consultant: Genentech, Sun Pharmaceuticals, Kala Pharmaceuticals, Notal Vision, Samsara Vision

Speakers Bureau: Genentech, Sun Pharmaceuticals, Kala Pharmaceuticals, Notal Vision, Alimera Sciences

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Michelle C. Carlson, PharmD; Abigail Dill, Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms